In the study using CD19 CAR T cells to treat leukemia that was discussed previously, 13 out of 30 patients had neurologic toxic effects, and 6 patients had delayed encephalopathy that was independent of the severity of CRS and whether the patient was treated with tocilizumab [46]. The gene discussed is CD19; the disease is congenital rubella syndrome.